Region South Denmark Clinics widely implement Monsenso mHealth solution

Region South Denmark Clinics widely implement Monsenso mHealth solution

Region South Denmark Clinics will use the Monsenso mHealth solution to support treatment of individuals diagnosed with depression, anxiety, bipolar, schizophrenia, or borderline personality disorder.

Copenhagen, Denmark – 4, September, 2017

The Mental Health Services in the Region of Southern Denmark are currently rolling out the Monsenso mHealth solution to support the treatment of individuals with affective disorders.

Monsenso is an innovation leader in mobile health solutions for mental health. Their mHealth solution is presently used by 25 clinicians across Mental Health Services in the Region of Southern Denmark to support the treatment of individuals diagnosed with depression, anxiety, bipolar, schizophrenia or borderline personality disorder.

Thomas Lethenborg, CEO at Monsenso, said that the decision for the roll-out came as a natural progression of the collaboration between Monsenso and the Region of Southern Denmark Mental Health Services on the ENTER project and the Public-Private Innovation (PPI) Partnership.

“Monsenso and the Region South Denmark have been working on different research projects for quite some time now; it’s only natural they decide to roll out our mHealth solution widely. By implementing Monsenso Clinic, clinicians will have access to patients’ historical aggregated data which will assist them in making better decisions in regards to a person’s treatment,” Mr. Lethenborg added.

The Monsenso solution has been previously utilised during research trials at The Centre for Telepsychiatry in the Region of Southern Denmark.

Claus Faerch Head of Department at The Centre for Telepsychiatry in the Region of Southern Denmark said: “We are continuously looking to improve patient engagement, and this technology will help us to track and discover more changes in mood. Our aim is to use the technology to help support the treatment we currently provide to our patients, with views to expanding the programme to more clinicians shortly.”

The  mHealth solution is based on a double-loop treatment model. The first loop consists of a smartphone app operates as a self-management tool to provide the patient insight into how their actions may influence their disorder. Individuals can use the app to fill out routine self-assessments regarding their behaviour, such as logging the amount of hours they have slept.  Additionally, the app also collects sensor data and sends helpful notifications for when patients are reporting behaviour that may trigger symptoms of their disorder.

The second loop of the treatment model involves the clinician. Clinicians can access a web portal that is synchronised to the patient’s app. This synchronisation enables clinicians to efficiently access the data collected by the patients’ smartphones anytime and anywhere.

This comprehensive double loop feedback system aims to increase patient engagement, awareness, and informed decision making during treatment.

Click on this link to read this press release in Danish.

For additional information, please contact:
Helen Chen
Marketing
Monsenso
+45 30 25 15 26
marketing@monsenso.com

WE HAVE A DEMO

Want to learn more about our Mhealth solution?- Then try our free demo

UK-based hospital implements mHealth solution for borderline and depression patients

UK-based hospital implements mHealth solution for borderline and depression patients

Copenhagen, Denmark – 27 January 2015. Monsenso, a Copenhagen-based technology company, announced today that UK-based, St Andrew’s Healthcare, will implement a new mHealth solution for borderline and depression patients. The mHealth solution, designed and developed by Monsenso, will be used to support the person-centred treatment of inpatients.

Thomas Lethenborg, CEO at Monsenso ApS, said that St Andrew’s will conduct a six-month service evaluation feasibility study to determine if the mHealth solution for borderline and depression patients should also be used to help treat other mental health illnesses.

“St Andrew’s Healthcare has a commitment to providing the best inpatient and outpatient mental health services in the UK. With the implementation of the Monsenso mHealth solution, clinicians will have access to patient’s historical aggregated data that will help clinical staff in the treatment of complex mental health illnesses,” Mr Lethenborg added.

St Andrew’s Healthcare Director of Nursing and Quality, Lesley Boswell said the trial would allow them to investigate how real-time mood monitoring could be used to enhance patient care.

“We are continuously looking to improve our understanding of patient experiences and this technology will help us to access previously hidden mood signals. With a bit of configuration, our aim is to use the technology to help support the therapies and treatment we currently provide to our patients, with views to expanding the programme to other care pathways in the future,” said Ms Boswell.

The Monsenso mHealth solution for borderline and depression is based on a double-loop treatment model. On one side, patients use a smartphone to fill in routine self-assessments that reveal their current state of mind and collect sensor data.  The smartphone app also works as a self-management tool that allows patients to manage their symptoms and the behaviours that trigger those symptoms.

On the other side, clinicians use a web portal where they can access all the data collected by the patients’ smartphones anytime, anywhere. The web portal enables clinicians to view relevant information related to each patient.

With more than 4000 employees, St Andrew’s Healthcare delivers effective treatment, therapies, clinical consultancy, vocational rehabilitation and outpatient care across its four sites. The charity provides specialist and secure care pathways in mental health and neuropsychiatry and provides care for young people, adults, and seniors.

For additional information contact:
Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 71 7713
highland@monsenso.com

Bonnie Sleeman
Communications Coordinator
St Andrew’s Healthcare
+44 1604 872946
bsleeman@standrew.co.uk You can download this article as PDF in English and Danish

Monsenso strengthens focus on mHealth for mental health

Monsenso strengthens focus on mHealth for mental health

Copenhagen, Denmark – 1 December 2015. Monsenso Aps, an innovation leader in mobile health (mHealth) solutions for mental health, announced today the acquisition of DayBuilder Solutions, a local competitor developing an mHealth solution for depression to strengthen focus on mHealth for mental health.

The acquisition will consolidate Monsenso in the Danish market and strengthen their focus internationally. Starting from today, Monsenso will take over DayBuilder’s obligations to customers and researchers. Besides acquiring new customers with this merger, Monsenso will also benefit from additional research and technology that will support the future development of leading mobile health solutions for mental health.

With regards to the merger, Thomas Lethenborg, CEO at Monsenso, commented, “With this merger, two evolving Danish companies can now present a unified front locally and internationally, rather than being competitors. This merger has made us a stronger player in the development space of mHealth solutions; therefore, clinicians and patients will benefit from this outcome.”

I believe that Monsenso has the capability to dominate the market nationally and internationally, and with our joint efforts we have the potential to help thousands of people suffering from mental illness worldwide,” commented Philip Kaare Løventoft, CEO at DayBuilder Solutions.

After the merger is completed, Monsenso will take over a new research project called SAFE2, which was handled by DayBuilder Solutions in collaboration with Rigshospitalet, the University Hospital in Denmark.

Currently, the Monsenso mHealth solution is being used by the different health care regions in Denmark to support the treatment of patients suffering from schizophrenia, major depressive disorder(MDD), post-traumatic stress disorder (PTSD), anxiety, and borderline personality disorder.

For additional information contact:

Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 71 7713
highland@monsenso.com You can download this article as PDF in English and Danish